Los Angeles, CA, United States of America

Lidia Robert

This inventor holds 1 USPTO granted patent. Top assignee: University of California. Active years: 2025.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lidia Robert - Innovator in Melanoma Treatment

Introduction

Lidia Robert is a prominent inventor based in Los Angeles, CA, who has made significant contributions to the field of medical research. She is particularly known for her innovative approaches to treating melanoma, a serious form of skin cancer. With a focus on developing novel therapeutic methods, Lidia has dedicated her career to improving patient outcomes.

Latest Patents

Lidia Robert holds 1 patent for her work titled "Methods and compositions for treating melanoma." This patent outlines a therapeutic method that is especially beneficial for patients diagnosed with melanoma who have developed resistance to other treatments. The method involves administering a composition that includes a ferroptosis-inducing agent or other dedifferentiated melanoma-targeting agents to effectively treat the condition.

Career Highlights

Lidia is affiliated with the University of California, where she conducts her research and develops her innovative treatments. Her work has garnered attention for its potential to change the landscape of melanoma therapy, providing hope for patients facing limited options.

Collaborations

Throughout her career, Lidia has collaborated with esteemed colleagues, including Thomas G Graeber and Jennifer Tsoi. These partnerships have enriched her research and contributed to the advancement of her therapeutic methods.

Conclusion

Lidia Robert is a trailblazer in the field of melanoma treatment, with her innovative patent showcasing her commitment to improving patient care. Her work continues to inspire advancements in medical research and therapy.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…